FibroBiologics Past Earnings Performance
Past criteria checks 0/6
FibroBiologics's earnings have been declining at an average annual rate of -51%, while the Biotechs industry saw earnings growing at 7.7% annually.
Key information
-51.0%
Earnings growth rate
-39.3%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -649.6% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How FibroBiologics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -18 | 9 | 4 |
| 30 Jun 24 | 0 | -19 | 8 | 3 |
| 31 Mar 24 | 0 | -23 | 7 | 3 |
| 31 Dec 23 | 0 | -19 | 7 | 2 |
| 30 Sep 23 | 0 | -11 | 6 | 2 |
| 30 Jun 23 | 0 | -10 | 5 | 2 |
| 31 Mar 23 | 0 | -9 | 4 | 1 |
| 31 Dec 22 | 0 | -5 | 3 | 1 |
| 31 Dec 21 | 0 | -2 | 1 | 1 |
Quality Earnings: SG0 is currently unprofitable.
Growing Profit Margin: SG0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SG0 is unprofitable, and losses have increased over the past 5 years at a rate of 51% per year.
Accelerating Growth: Unable to compare SG0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SG0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Return on Equity
High ROE: SG0 has a negative Return on Equity (-649.58%), as it is currently unprofitable.